FDA Warns Caraco Pharmaceuticals Over Stability Testing Issues

FDA concerns over stability testing at Caraco Pharmaceuticals have led to a warning letter citing several significant issues. The agency criticizes the company for failing to establish and follow an adequate stability-testing program, with findings from a May-June 1999 audit being repeated during a recent inspection. The Detroit district also raises concerns about equipment maintenance and sanitation procedures, potentially affecting the firm's products. The warning letter threatens to block pending NDA and ANDA requests until corrections are made.

Key Takeaways:

• FDA issued a warning letter to Caraco Pharmaceuticals on July 6, citing stability testing issues and inadequate quality control procedures.
• The agency criticized the company for failing to establish and follow a stability-testing program that meets regulatory requirements.
• The repeated observation of stability testing issues from a 1999 audit during a recent inspection (Jan. 18-March 10) raises concerns about the company's ability to ensure drug product stability.
• FDA also cited Caraco for failing to establish and follow procedures for equipment maintenance and sanitation, potentially affecting product quality.
• The agency threatened to block pending NDA and ANDA requests until the company corrects the issues and makes necessary changes.
• Caraco Pharmaceuticals has been instructed to seek outside assistance to correct the problems and improve its quality control procedures.

Statistics:

• The FDA warning letter was issued on July 6, citing significant stability testing issues at Caraco Pharmaceuticals.
• A total of 3 items on the 483 issued during the Jan. 18-March 10 inspection highlighted the need for a stability-testing program.
• The repeated observation of stability testing issues from a 1999 audit underscores the company's ongoing struggles with quality control procedures.

Sources:

• FDA Warning Letter to Caraco Pharmaceuticals, July 6, 2023.